A Study of Electronic Clinical Decision Support Tools for Steatotic Liver Disease

This study is testing an electronic tool called eMPOWER Decision Aid. This tool is built into electronic health records and uses your clinical information to help doctors decide the best way to manage your steatotic liver disease (MASLD). We want to see if using this tool helps more high-risk patients with MASLD get connected to liver specialists (hepatology care). You might be able to join if you are an adult (18 or older) with MASLD or liver fat seen on imaging, plus other risk factors like heart problems or long-term elevated liver enzymes. The study is currently unclear on its recruitment status.

Study design
This is a randomized study involving 7200 participants, where you would be assigned by chance to either receive care with the eMPOWER Decision Aid or usual care.
What's involved
You would have an outpatient clinic visit (in-person or telemedicine) at a participating clinic site, and your care would be followed for 12 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07382349

A Study of Electronic Clinical Decision Support Tools for Steatotic Liver Disease

Recruiting
NAAges 18+InterventionalDiagnostic
Vanderbilt University Medical Center
~7,200 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:eMPOWER Decision Aid

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The primary objective of this pragmatic trial is to assess the efficacy of the electronic decision support aid for increasing linkage to hepatology care for high-risk participants with MASLD
Measured over Baseline to 12 months
MASLD

NCT07382349

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Vanderbilt University Medical Center

    Nashville, Tennesseeno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Ashley Spann, MD, MSACI · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients (age ≥ 18 years)
Outpatient clinic visit (in-person or telemedicine) at a participating clinic site
Demonstrated Screening Need due to High Risk Profile, which includes the following: Diagnostic Codes for MASLD or Hepatic Steatosis on Imaging PLUS at least one cardiometabolic risk factors; OR Chronically Elevated Liver Enzymes (\> 6 months); OR patient with impaired glycemic control (prediabetes/diabetes); OR 2 or more cardiometabolic risk factors present

Exclusion

Solid Organ Transplant Recipient
Existing Hepatology Relationship Evidenced by Prior Hepatology Visit Within 3 Years
Active Cancer Diagnoses
Diagnoses for Alcohol-Related Conditions
Pregnant Individuals
Receiving Palliative Care Services
  • The primary objective of this pragmatic trial is to assess the efficacy of the electronic decision support aid for increasing linkage to hepatology care for high-risk participants with MASLDBaseline to 12 months

    Number of participants with new referrals placed to Hepatology for evaluation of high-risk status